Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 4Withdrawn 2Unknown 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 2Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

lutetium Lu 177 dotatate 4lanreotide 3(177)Lu-DOTA-EB-TATE 3Positron Emission Tomography Computed Tomography 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Metformin 2Fluorodeoxyglucose F18 2Everolimus 2Capecitabine 2Biopsy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2sintilimab 1recombinant interferon alpha 2b-like protein 1gallium Ga 68 dotatate 1copper dotatate CU-64 1cabozantinib 1anlotinib 1amino-acid, glucose, and electrolyte solution 1Yttrium-90 1Tomography, Emission-Computed, Single-Photon 1Temozolomide 1Surgical Procedures, Operative 1Somatostatin 1Plastic Surgery Procedures 1Phlebotomy 1Nivolumab 1Needles 1Magnetic Resonance Spectroscopy 1Lysine 1Lutetium-177 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Neuroendocrine Tumors × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all
NCT04790708 2021-03-10

FENET-2016

University Hospital of Ferrara

Phase NA Unknown
250 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04194125 2020-11-04

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

University of Warmia and Mazury

Phase 2 Unknown
25 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡